Emily Bergsland

Dr. Emily Bergsland is a Professor of Medicine at the University of California, San Francisco (UCSF) School of Medicine, where she serves as Director of the UCSF Center for Neuroendocrine Tumors and Associate Director for Education for the UCSF Helen Diller Family Comprehensive Cancer Center. A leading expert in gastrointestinal malignancies, Dr. Bergsland has dedicated her career to advancing the understanding and treatment of neuroendocrine tumors through clinical practice, research, and education. Her leadership roles include past presidency of the North American Neuroendocrine Tumor Society, membership on the NCCN Neuroendocrine Tumor Guidelines panel, and former chair of the NET Task Force of the NCI Gastrointestinal Steering Committee.

• BS in Biochemistry/Molecular Biology, University of Wisconsin, Madison (1985)
• MD, University of Minnesota, Minneapolis (1989)
• Residency in Internal Medicine, UCSF (1992)
• Chief Residency, UCSF (1993)
• Fellowship in Medical Oncology, UCSF (1995)
• Molecular Medicine Training Program, UCSF (1998)
• Diversity, Equity, and Inclusion Champion Training, University of California (2019)

Dr. Bergsland's research program focuses on neuroendocrine neoplasms of all grades, with particular emphasis on clinical trials, biomarker development, imaging techniques, and clinical outcomes. Her work bridges the gap between laboratory discoveries and patient care, with numerous publications addressing therapeutic strategies for neuroendocrine tumors. She has been instrumental in developing guidelines for neuroendocrine tumor management and has contributed significantly to understanding tumor biology, progression patterns, and treatment responses in this specialized field. Her research often examines disparities in cancer care and seeks to optimize treatment approaches for diverse patient populations.

Analysis of Dr. Bergsland's recent publications reveals a strong focus on advancing the clinical management of neuroendocrine tumors through multiple approaches: refining diagnostic criteria and imaging techniques, developing consensus treatment guidelines, investigating molecular mechanisms of tumor progression, and evaluating novel therapeutic combinations. Her work spans basic science, translational research, and clinical implementation, with particular attention to health disparities and personalized treatment approaches. The publications demonstrate her leadership in multi-institutional collaborations and her commitment to establishing evidence-based standards for neuroendocrine tumor care.

• Past President of the North American Neuroendocrine Tumor Society
• Member of NCCN Neuroendocrine Tumor Guidelines panel
• Past Chair of the NET Task Force of the NCI Gastrointestinal Steering Committee
• Principal Investigator for NIH K12CA260225: UCSF Paul Calabresi K12 Career Development Program in Clinical Oncology (2021-2026)

As Principal Investigator for the UCSF Paul Calabresi K12 Career Development Program in Clinical Oncology, Dr. Bergsland plays a critical role in mentoring the next generation of clinical oncology researchers. Her educational leadership extends to her position as Associate Director for Education at the UCSF Helen Diller Family Comprehensive Cancer Center, where she shapes training programs and educational initiatives. Dr. Bergsland has secured significant research funding to support her work on neuroendocrine tumors and has been instrumental in developing clinical trial networks focused on this specialized cancer type. Her collaborative approach has resulted in numerous multi-institutional studies that have advanced the field of neuroendocrine tumor management.

Dr. Bergsland leads the UCSF Center for Neuroendocrine Tumors, which brings together a multidisciplinary team of medical oncologists, surgeons, endocrinologists, radiologists, pathologists, and researchers dedicated to providing comprehensive care for patients with neuroendocrine tumors. The center serves as a hub for clinical trials, translational research, and specialized patient care, with collaborations extending to national and international research networks. Through her leadership, the center has become a recognized center of excellence for neuroendocrine tumor diagnosis, treatment, and research.